
DaVita Inc.
DVA
Updated: 24/09/2026, 20:52:22
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
No summaries found.
The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.
- Share price
- $175.08
- Market cap
- $11.24B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Javier J. Rodriguez
- Employees
- 78,000
- IPO date
- 31/10/1995
- Beta
- 0.83
- Last dividend
- $0.00
- Day range
- $174.88 – $183.78
- 52-week range
- $101.00 – $247.49
- 1-day performance
- -4.40%
- 1-year performance
- 73.35%
- Current drawdown (1Y)
- -29.26%
- CIK
- 0000927066
- CUSIP
- 23918K108
- ISIN
- US23918K1088
- Created
- 07/12/2025, 03:41:00
- Last update
- 24/09/2026, 20:52:22
Track DaVita Inc. with an AI analyst
See which prediction-market events move DVA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Best Growth Stocks to Buy for June 15th
Zacks Investment Research • STOCK • 15/06/2026, 06:26:05
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
Zacks Investment Research • STOCK • 11/06/2026, 21:01:08
DaVita HealthCare (DVA) Moves to Strong Buy: Rationale Behind the Upgrade
Zacks Investment Research • STOCK • 11/06/2026, 15:01:09
Best Growth Stocks to Buy for June 11th
Zacks Investment Research • STOCK • 11/06/2026, 06:46:06
DaVita Stock Gains From Integrated Kidney Care and CKCC Progress
Zacks Investment Research • STOCK • 10/06/2026, 15:56:05
Best Value Stocks to Buy for June 9th
Zacks Investment Research • STOCK • 09/06/2026, 08:15:18
DaVita Expands Comprehensive Kidney Care Through Dialysis Services
Zacks Investment Research • STOCK • 04/06/2026, 16:46:13
Best Growth Stocks to Buy for June 4th
Zacks Investment Research • STOCK • 04/06/2026, 08:35:29
DaVita Gains 21.4% in Three Months: How Should You Play the Stock?
Zacks Investment Research • STOCK • 03/06/2026, 16:31:24
Best Growth Stocks to Buy for June 2nd
Zacks Investment Research • STOCK • 02/06/2026, 08:21:17
Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term
Zacks Investment Research • STOCK • 29/05/2026, 12:50:35
Best Value Stocks to Buy for May 21st
Zacks Investment Research • STOCK • 21/05/2026, 07:21:08